Navigation Links
Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer

ancer

According to the American Cancer Society, 81,550 Americans will be diagnosed with head and neck cancer in 2007, including cancers of the tongue, the rest of the mouth, the salivary glands and inside the throat, the voice box, eye and orbit, thyroid and the lymph nodes in the upper neck. In addition, it is estimated that more than 12,900 Americans will die from this disease this year. Head and neck cancer most often affects people over the age of 50, and men are twice as likely to be diagnosed as women. The most common risk factors are tobacco and excessive alcohol use.

About ERBITUX(R) (Cetuximab)

ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.

ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.

ERBITUX is indicated for
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
(Date:12/15/2009)... Oregon, December 15 Bend Research Inc. announced,today ... file for HPMCAS, an,excipient used in technologies developed by ... drugs. , Bend Research clients ... (DMF),for HPMCAS for regulatory filings with the FDA, Bend ... excited about this new development and know it will ...
(Date:12/14/2009)... MALVERN, Pa., Dec. 14 Fujirebio Diagnostics ... Sciences Company of the Year by the Eastern ... the Hilton Hotel in Philadelphia on Thursday, December ... Council is the Philadelphia region,s largest technology and ... Awards" of the Technology and Life Sciences Community, ...
(Date:12/14/2009)... VIEW, Calif., Dec. 14 Alexza Pharmaceuticals, Inc. ... submitted its New Drug Application (NDA) for Staccato® loxapine ... AZ-004 is an inhalation product candidate being developed ... schizophrenia or bipolar disorder. The IND for ... August 2005. ,, "AZ-004 has delivered a predictable and ...
Breaking Medicine Technology:Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient 2Fujirebio Diagnostics Named Life Sciences Company of the Year 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6U of I scientist 3A Public policy should promote family mealtimes 9845 1U of I scientist 3A Public policy should promote family mealtimes 9845 2U of I scientist 3A Public policy should promote family mealtimes 9845 3Nationwide Health Data Exchange Allows Health Provider Payers to Cooperate in Decreasing Waste and Helping Policyholder Costs 56610 1Nationwide Health Data Exchange Allows Health Provider Payers to Cooperate in Decreasing Waste and Helping Policyholder Costs 56610 2Day Care May Not Shield Kids From Asthma Allergies 56605 1Day Care May Not Shield Kids From Asthma Allergies 56605 2Day Care May Not Shield Kids From Asthma Allergies 56605 3
... Nov. 9 NTM Info & Research ... research for,nontuberculous mycobacterial (NTM) lung disease announces ... an innovative,program to provide guidance about pressing ... and clinical and treatment issues.,Small pilot studies ...
... WASHINGTON, Nov. 9 The Community Oncology,Alliance ... that the Centers for Medicare & Medicaid ... access of senior cancer patients to,vital anemia-fighting ... a,National Coverage Determination (NCD) limiting oncologists, use ...
Other Medicine Technology:Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions 2
(Date:12/14/2009)... new liposuction and fat transfer treatments can help people slim ... minimally invasive treatment. , ... (PRWEB) ... can remove excess fat from the abdomen and inject it ... reduce facial wrinkling and enhance lips all in one safe, ...
(Date:12/14/2009)... Dec. 14 Americold Realty Trust ("Americold") announced ... Form S-11 with the U.S. Securities and Exchange Commission ... of its common shares. The number of shares to ... have not yet been determined. The common shares to ... sold by Americold. ,, The joint book-running managers ...
(Date:12/14/2009)... Aflac Incorporated announced today that it has priced ... with a coupon of 6.9%. The notes will ... yield 6.984%. The company anticipates using the proceeds ... corporate purposes. ,, Commenting on the pricing of ... Financial Officer Kriss Cloninger III commented: "This debt ...
(Date:12/14/2009)... NAPA, Calif., Dec. 14 Tough Enough To ... fight breast cancer, celebrated its fifth anniversary at ... at the Wrangler National Finals Rodeo (Wrangler NFR) ... associated with rough-and-tumble rodeo cowboys, the support of ... as the sold-out crowd sported pink shirts, hats, ...
(Date:12/14/2009)... Canada for 13 years under government controlled health care, before moving ... In speaking engagements and in his new book, Health Reform: The ... of such a system and its threat to real health care! ... ... Kurisko , a diagnostic radiologist from Minnesota, warns Americans not to ...
Breaking Medicine News(10 mins):Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 2Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 3Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2
... Fla., Jan. 22 CORD:USE Cord Blood Bank is ... by the Foundation for the Accreditation of Cellular Therapy ... bank that specializes in the collection, processing, storage and ... already been used for transplantation in more than 14,000 ...
... for 11:00 a.m. ET POWAY, Calif., Jan. 22 ... provider of diagnostic imaging products and services that improve ... before the market opens on Thursday, February 5, 2009, ... December 31, 2008. A conference call is scheduled for ...
... Pravasi Bharatiya Divas convention in Chennai, January 7-10, a consortium of ... comprehensive health care organization with an emphasis on improving health provision ... ... (PRWEB) January 22, 2009 -- At the Pravasi Bharatiya Divas convention ...
... before the President,s Cancer Panel, investigators at the U.S. EPA,s Office ... the EPA Administrator to use regulatory authorities authorized by Congress to ... , ... Atlanta, GA (PRWEB) January 22, 2009 -- A ...
... of Wisconsin researchers of over 1,800 patients seen in ... residents may not personally be as well prepared for ... , Survey results will be presented at the National ... Fla., January 22, 2009. , The purpose of ...
... WASHINGTON, Jan. 21 Five former directors ... United States Agency for International Development (USAID) today urged ... U.S. leadership in global family planning . The ... Case for U.S. International Family Planning Assistance, as ...
Other Medicine News:Health News:CORD:USE Cord Blood Bank Receives Prestigious Accreditation from the Foundation for the Accreditation of Cellular Therapy 2Health News:Digirad Corporation to Release Fourth Quarter and Year-End Financial Results on February 5, 2009 2Health News:Doctors of Indian origin unite to tackle global health problems - the creation of The first ever Global Association of Physicians of Indian Origin (GAPIO) 2Health News:Doctors of Indian origin unite to tackle global health problems - the creation of The first ever Global Association of Physicians of Indian Origin (GAPIO) 3Health News:Scientists and Investigators Cite Need for Radon Regulation to Prevent Lung Cancer- Call Current EPA Efforts Ineffective 2Health News:Scientists and Investigators Cite Need for Radon Regulation to Prevent Lung Cancer- Call Current EPA Efforts Ineffective 3Health News:Scientists and Investigators Cite Need for Radon Regulation to Prevent Lung Cancer- Call Current EPA Efforts Ineffective 4Health News:Personal disaster preparedness 2Health News:Five Former USAID Officials Ask Obama for Leadership on Family Planning 2
Inorganic phosphorus (UV method) reagent is for the quantitative determination of inorganic phosphorus in human serum....
Inorganic phosphorus reagent is used for the quantitative determination of inorganic phosphorus in human serum....
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
Medicine Products: